Gilead’s Veklury (remdesivir) Receives the TGA’s Approval to Treat Adults and Adolescents with Severe COVID-19 Symptoms

 Gilead’s Veklury (remdesivir) Receives the TGA’s Approval to Treat Adults  and Adolescents with Severe COVID-19 Symptoms

MHLW Expedites the Reviews of Gilead’s Remdesivir to Treat Patients with COVID-19 in Japan

Shots:

  • The TGA authorization follows the recent data shared by EMA and Singapore Health Sciences Authority for remdesivir’s approval in EU, Singapore and, Japan for COVID-19 patients
  • TGA’s approval was made within 2 weeks of the receipt of the submission while the provisional approval is based on preliminary data valid for 6 years. Additionally, the company plans filling full registration confirming the safety and efficacy of the drug to the TGA committee
  • Remdesivir is an investigational drug targeted reduce hospitalization time for COVID-19 while the drug will be available for severely unwell, requiring oxygen or high-level support to breathe, and in-hospital care

Click here to read full press release/ article | Ref: Therapeutic Goods Administration | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post